Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Czechia / NCT06068114
Recruiting Observational

Gastric Pathophysiology in Diabetes

NCT06068114 · tracked via the Priya Life Science Czechia tracker
Phase
Observational
Started
2022-10-05
Last updated
2024-05-17

Condition(s) studied

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Functional DyspepsiaGastroparesisHealthy

Study summary

This is a comprehensive pathophysiological study assessing various gastric functions in patients with diabetes mellitus. The investigators aim to examine the stomach with various measurement devices to gain information about its different functions and malfunctions. After the initial measurements, the examinations will be repeated after a year in each patient. Changes in the measurement values will be examined and their relations to each other and to the overall health of the patients will be investigated.

For example it is hypothesised that diabetic patients also suffering from functional dyspepsia or gastroparesis will also show some changes in the function of the pyloric muscle.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
Accepted
Inclusion Criteria (diabetic group): * Diabetes mellitus type I or II, minimal duration of the disease 3 years, minimal duration of specific treatment (drugs, insulin) 2 years Exclusion Criteria (diabetic group): * Diabetes mellitus type II being treated with a diet only * Severe acute decompensation of diabetes (uncontrolled diabetes) necessitating hospitalization * Concomitant treatment with more than one prokinetic agent * Active treatment with opioids or a history of treatment with opioids within 12 months before enrolment * Previous esophageal or major gastric surgery (e.g. esophageal myotomy, esophagectomy, antireflux surgery, Billroth I or II gastric resection, gastric pull-through, pyloromyotomy, pyloroplasty, gastric electrical stimulation) * Organic pyloric (or intestinal) obstruction (fibrotic stricture, etc.) * Severe coagulopathy * Esophageal or gastric varices and /or portal gastropathy * Advanced liver cirrhosis * Pregnancy or puerperium * Malignant or pre-malignant gastric diseases (dysplasia, gastric cancer, GIST): patients with a history of such disease after its cure are eligible for enrolment * The presence of a rumination syndrome or eating disorders (anorexia nervosa, bulimia). In case of doubts, a psychiatric examination will be performed. * Systemic connective tissue disorder * Inability to obtain informed consent * Any other condition, which in the opinion of the investigator would interfere with study requirements

Primary outcome measure(s)

Trial sites (5)

FacilityCityRegionStatus
Nemocnice AGEL Ostrava-Vítkovice a. s. Ostrava Czechia Recruiting
University Hospital Ostrava Ostrava Czechia Recruiting
Institute for Clinical and Experimental Medicine Prague Czechia Recruiting
Military University Hospital Prague Prague Czechia Recruiting
University Hospital Trnava Trnava Slovakia Recruiting

More Institute for Clinical and Experimental Medicine trials in Czechia

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06068114 on ClinicalTrials.gov ↗ ← All trials in Czechia